SRRK

Scholar Rock, Inc.distress 2/10 · well-funded / low risk

$47.75-1%today-18% from 52w high

scholarrock.com289 employeesFounded 2012Cambridge, MABiotechnology

Metabolic / Obesity 1Oncology 1

Lead: spinal muscular atrophy · target GLP-1/GIP

Revenue

pre-revenue

Liquidity

$480M

Runway

1.6 yrs

Shares 1y

+25%

Price & events

-0.0% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.1%

-7.7%

-6.9%

+0.6%

+7.8%

+20.2%

+419.0%

+46.2%

+1.8%

All

Overview

Market Cap: $5.72B
Enterprise Value: $5.49B
Volume: 129.72K
52 Week Range: $27.92 – $57.94
Total Shares: 119.83M
Float Shares: 91.82M
Short %: 19.22%
% Held by Insiders: 0.78%
% Held by Institutions: 117.14%
RVOL: 0.08x
Beta: 0.68

Pipeline stages · 2 programs

Apitegromab, Nusinersen, Risdiplam

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-11-01

SRK-181, anti-PD-(L)1 antibody therapy

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 5 trials · 3 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-11-01 Estimated 50% readout ~2027-01-15	Phase 3	Apitegromabfast trackorphanrare pediatricpriority review	Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin	—	active not recruiting
2028-06 Estimated 50% readout ~2028-07-16	Phase 2	Apitegromabfast trackorphanrare pediatricpriority review	Facioscapulohumeral Muscular Dystrophy, FSHD	—	not yet recruiting
2028-11 Estimated 50% readout ~2028-12-16	Phase 2	Apitegromab, Nusinersen, Risdiplamfast trackorphanrare pediatricpriority review	Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin	—	recruiting
2025-04-14	Phase 1	SRK-181, anti-PD-(L)1 antibody therapy	Cancer	112	completed
2025-03-04	Phase 2	Apitegromab, Placebo, Tirzepatidefast trackorphanrare pediatricpriority review	Overweight and Obesity	102	completed

Upcoming readouts & decisions · our signals

1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.

Catalyst news & presentations · 22

2026Guided 40%regulatory submissionFiled (NDA/BLA)apitegromab · Anticipated resubmission of biologics license application.SEC 8-K
second half of 2026Guided 55%readoutPhase 1SRK-439 · Topline data from Phase 1 study expected in H2 2026SEC 8-K
September 30, 2026Confirmed 100%PDUFAPDUFAapitegromab · PDUFA action date for BLASEC 8-K
2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
mid-2026trial initiationsecondaryPhase 2apitegromab · Phase 2 FORGE trial initiation expected mid-2026SEC 8-K
near mid-2026chmp opinionCHMP (EU)apitegromab · EU MAA decision anticipatedSEC 8-K
within 30 daysfiling acceptanceFiled (NDA/BLA)apitegromab · FDA acceptance of resubmitted BLA expected within 30 days of March 31, 2026 submission.SEC 8-K
2026-03-03partnershipSecured new debt facility of up to $550 million from Blue Owl CapitalSEC 8-K
2026-03-03fda agreementapitegromab · Type C meeting resulted in FDA alignment to include second fill-finish facility in BLA resubmission.SEC 8-K
second half of 2025regulatory submissionFiled (NDA/BLA)SRK-439 · IND filing for SRK-439SEC 8-K
Q4 2025trial initiationsecondaryPhase 1SRK-439 · Initiate dosing of SRK-439 in healthy volunteers.SEC 8-K
year-end 2025trial initiationsecondaryapitegromab · Initiate clinical development in a second neuromuscular disorder.SEC 8-K
2025-11-14partnershipFiled prospectus supplement for ATM offering of up to $200M common stock through JefferiesSEC 8-K
2025-11-12fda agreementapitegromab · Completed constructive in-person Type A meeting with FDA; Catalent confirmed reinspection ready by end of 2025.SEC 8-K
Q3 2025regulatory submissionFiled (NDA/BLA)SRK-439 · IND application expected to be filedSEC 8-K
Q3 2025trial initiationsecondaryPhase 2apitegromab · Initiation of Phase 2 OPAL trial in infants and toddlersSEC 8-K
3Q 2025trial initiationsecondarySRK-439 · IND submission for SRK-439SEC 8-K
2025-09-23crlapitegromab · Complete Response Letter due to manufacturing observations at Catalent IndianaSEC 8-K
September 22, 2025PDUFAPDUFAapitegromab · PDUFA target action date for BLASEC 8-K
June 2025readoutPhase 2apitegromab · Topline data from Phase 2 EMBRAZE trialSEC 8-K
1Q 2025regulatory submissionFiled (NDA/BLA)apitegromab · BLA and MAA submission for SMASEC 8-K
March 19, 2025conferencedata presentationsecondaryapitegromab · SAPPHIRE trial data and DMD preclinical data at MDA ConferenceSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 119,828,338 · 1 offerings/1y · 0 PIPEs

2025-11-14424B5offering
2024-11-14SC 13G/Astrategic_stake
2024-11-14SC 13G/Astrategic_stake
2024-11-14SC 13G/Astrategic_stake
2024-11-12SC 13G/Astrategic_stake
2024-11-12SC 13G/Astrategic_stake
2024-11-04SC 13G/Astrategic_stake

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $59 (+24% upside) · 16 analysts

2026-07-21WedbushOutperform
2026-05-08HC Wainwright & Co.Buy
2026-05-08BarclaysOverweight
2026-04-21Canaccord GenuityBuy
2026-04-01WedbushOutperform
2026-03-16JP MorganOverweight

Competitors — GLP-1/GIP

VKTXViking Therapeutics, Inc.$4.2B · D5
BIOABioAge Labs, Inc.$956M · D1
PTNPALATIN TECHNOLOGIES INC$14M · D9

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.